A systematic review of statin-induced muscle problems in clinical trials

American Heart Journal

Volumn 168, Issue 1, 2014, Pages 6-15

  Ganga, Harsha V ^a   Slim, Hanna B ^b   Thompson, Paul D ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADVERSE OUTCOME; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); HUMAN; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 84903132374     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.03.019     Document Type: Review

References (56)

1. E. Bruckert, G. Hayem, and S. Dejager et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 6 2005 403 414 (Pubitemid 43228152)
2. J.D. Cohen, E.A. Brinton, and M.K. Ito et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an Internet-based survey of 10,138 current and former statin users J Clin Lipidol 6 3 2012 208 215
3. J.R. Downs, M. Clearfield, and H.A. Tyroler et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin Am J Cardiol 87 9 2001 1074 1079 (Pubitemid 32710322)
4. J. Armitage, L. Bowman, and R. Collins et al. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people BMC Clin Pharmacol 9 2009 6
5. C.B. Newman, M. Szarek, and H.M. Colhoun et al. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS) Diab Vasc Dis Res 5 3 2008 177 183
6. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II Arch Intern Med 153 11 1993 1321 1329
7. R. Salonen, K. Nyyssonen, and E. Porkkala et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries Circulation 92 7 1995 1758 1764
8. B. Pitt, G.B. Mancini, and S.G. Ellis et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation J Am Coll Cardiol 26 5 1995 1133 1139
9. J.W. Jukema, A.V. Bruschke, and A.J. van Boven et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) Circulation 91 10 1995 2528 2540
10. J. Shepherd, S.M. Cobbe, and I. Ford et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 20 1995 1301 1307
11. F.M. Sacks, M.A. Pfeffer, and L.A. Moye et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 14 1996 1001 1009 (Pubitemid 26338729)
12. M. Mercuri, M.G. Bond, and C.R. Sirtori et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study Am J Med 101 6 1996 627 634 (Pubitemid 27150041)
13. A.A. Bak, J. Huizer, and P.A. Leijten et al. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease J Intern Med 244 5 1998 371 378 (Pubitemid 28513124)
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 19 1998 1349 1357
15. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) Ital Heart J 1 12 2000 810 820
16. J. Shepherd, G.J. Blauw, and M.B. Murphy et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 9346 2002 1623 1630 (Pubitemid 35379733)
17. H. Nakamura, K. Arakawa, and H. Itakura et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 9542 2006 1155 1163 (Pubitemid 44444932)
18. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients Am J Cardiol 72 14 1993 1031 1037
19. R.P. Byington, C.D. Furberg, and J.R. Crouse III et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) Am J Cardiol 76 9 1995 54C 59C
20. J.R. Downs, M. Clearfield, and S. Weis et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 20 1998 1615 1622 (Pubitemid 28248586)
21. D.H. Blankenhorn, S.P. Azen, and D.M. Kramsch et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) Ann Intern Med 119 10 1993 969 976 (Pubitemid 23334652)
22. R.H. Bradford, C.L. Shear, and A.N. Chremos et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up Am J Cardiol 74 7 1994 667 673
23. J.C. LaRosa, W. Applegate, and J.R. Crouse III et al. Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study Arch Intern Med 154 5 1994 529 539 (Pubitemid 24112505)
24. C.D. Furberg, H.P. Adams Jr., and W.B. Applegate et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group Circulation 90 4 1994 1679 1687 (Pubitemid 24320914)
25. D. Waters, L. Higginson, and P. Gladstone et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial Circulation 89 3 1994 959 968
26. P.S. Sever, B. Dahlof, and N.R. Poulter et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 9364 2003 1149 1158 (Pubitemid 36398384)
27. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 9435 2004 685 696 (Pubitemid 39140624)
28. C. Wanner, V. Krane, and W. Marz et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 3 2005 238 248 (Pubitemid 41058323)
29. S.J. Cowell, D.E. Newby, and R.J. Prescott et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis N Engl J Med 352 23 2005 2389 2397 (Pubitemid 40958435)
30. R.H. Knopp, M. d'Emden, and J.G. Smilde et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 7 2006 1478 1485 (Pubitemid 44127567)
31. P. Amarenco, J. Bogousslavsky, and A. Callahan III et al. High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 6 2006 549 559 (Pubitemid 44202151)
32. A. Keech, R. Collins, and S. MacMahon et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study Eur Heart J 15 2 1994 255 269 (Pubitemid 24110705)
33. T.R. Pedersen, K. Berg, and T.J. Cook et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study Arch Intern Med 156 18 1996 2085 2092 (Pubitemid 26346967)
34. K.K. Teo, J.R. Burton, and C.E. Buller et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102 15 2000 1748 1754
35. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 9326 2002 7 22
36. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) Lancet 344 8923 1994 633 638
37. J. Kjekshus, E. Apetrei, and V. Barrios et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 22 2007 2248 2261 (Pubitemid 350190755)
38. J.R. Crouse III, J.S. Raichlen, and W.A. Riley et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial JAMA 297 12 2007 1344 1353 (Pubitemid 46513235)
39. L. Tavazzi, A.P. Maggioni, and R. Marchioli et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 9645 2008 1231 1239
40. P.M. Ridker, E. Danielson, and F.A. Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 21 2008 2195 2207
41. B.C. Fellstrom, A.G. Jardine, and R.E. Schmieder et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 14 2009 1395 1407
42. J.A. Herd, C.M. Ballantyne, and J.A. Farmer et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]) Am J Cardiol 80 3 1997 278 286 (Pubitemid 27330142)
43. P.W. Serruys, P. de Feyter, and C. Macaya et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 24 2002 3215 3222 (Pubitemid 34686102)
44. G. Riegger, C. Abletshauser, and M. Ludwig et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment Atherosclerosis 144 1 1999 263 270 (Pubitemid 29259987)
45. S.A. Anderssen, A.K. Hjelstuen, and I. Hjermann et al. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives Atherosclerosis 178 2 2005 387 397 (Pubitemid 40193456)
46. P.W. Serruys, D.P. Foley, and G. Jackson et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial Eur Heart J 20 1 1999 58 69 (Pubitemid 29027527)
47. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function) Circulation 107 3 2003 422 428
48. B.A. Parker, J.A. Capizzi, and A.S. Grimaldi et al. Effect of statins on skeletal muscle function Circulation 127 1 2013 96 103
49. C. East, P.A. Alivizatos, and S.M. Grundy et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation N Engl J Med 318 1 1988 47 48 (Pubitemid 18025478)
50. P.S. Phillips, R.H. Haas, and S. Bannykh et al. Statin-associated myopathy with normal creatine kinase levels Ann Intern Med 137 7 2002 581 585
51. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 23 Suppl. 1 2004 III50 III57
52. C.D. Furberg, and B. Pitt Withdrawal of cerivastatin from the world market Curr Control Trials Cardiovasc Med 2 5 2001 205 207 (Pubitemid 33019612)
53. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 11 2004 1307 1316 (Pubitemid 39223221)
54. J. Armitage, L. Bowman, and K. Wallendszus et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 9753 2010 1658 1669
55. B.A. Parker, S.M. Gregory, and L. Lorson et al. A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design J Clin Lipidol 7 3 2013 187 193
56. M. Ucar, T. Mjorndal, and R. Dahlqvist HMG-CoA reductase inhibitors and myotoxicity Drug Saf 22 6 2000 441 457 (Pubitemid 30386462)